Clinical Trial Update: An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease [Phase 3]

View source ↗

Summary

This clinical trial update reports results from an extension Phase 3 study of oral ozanimod for moderately to severely active Crohn's disease; the study was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Zeposia (ozanimod hydrochloride)

Snippet

Sponsor: Celgene | Conditions: Crohn Disease | Phase 3 | Status: TERMINATED | Results posted: 2025-09-17